Myoclonic EpilepsySymptoms, Doctors, Treatments, Advances & More
Learn About Myoclonic Epilepsy
U Of M Neurology Clinic
Jack M. Parent, M.D., is a professor of neurology, director of the Neurodevelopment and Regeneration Laboratory, and co-director of the Comprehensive Epilepsy Center in the University of Michigan Medical School.His current research interests include neural stem cell transplantation to treat brain injury and neurodegeneration, and the modification of adult neural stem cells to promote brain repair after stroke or prevent epilepsy.Dr. Parent earned a Bachelor of Arts degree, with distinction, in human biology from Stanford University and his medical degree from the Yale University School of Medicine. He completed a medical internship and neurology residency at the University of California, San Francisco (UCSF), where he was selected chief resident. He stayed at UCSF for clinical fellowship training in epilepsy and clinical neurophysiology, and postdoctoral training in neuroscience research.An internationally recognized research leader in the fields of neural stem cell biology, regeneration after brain injury and epilepsy, Dr. Parent established the Neurodevelopment and Regeneration Laboratory at the U-M in 2000.Dr. Parent is a member of the Epilepsy Foundation of America Research Council, the Medical Advisory Board of the Global Ischemia Foundation, the Independent Science Review Panel of the New Jersey Commission on Brain Injury Research, and the National Scientific Advisory Council of the American Federation for Aging Research. He also serves as an associate editor of Neuroscience Letters, and is on the editorial boards of Experimental Neurology and Epilepsy Currents.He has received several awards for his research, including a Junior Investigator Award from the American Epilepsy Society, a Paul Beeson Physician Faculty Scholars in Aging Award, a Dreifuss-Penry Epilepsy Award from the American Academy of Neurology, and a Grass Foundation Award in Neuroscience from the American Neurological Association. Dr. Parent is rated as an Elite provider by MediFind in the treatment of Myoclonic Epilepsy. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome. Dr. Parent is board certified in Neurology and Clinical Neurophysiology.
St. Vincent Neurosurgery
Javier Echeverri is a Neurologist practicing medicine in Billings, Montana. He has been practicing medicine for over 47 years. Dr. Echeverri is rated as a Distinguished provider by MediFind in the treatment of Myoclonic Epilepsy. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Essential Tremor, Parkinson's Disease, Movement Disorders, Epilepsy with Myoclonic-Atonic Seizures, and Deep Brain Stimulation. Dr. Echeverri is currently accepting new patients.
Children's Hospital Colorado
Kelly Knupp is a Pediatrics provider practicing medicine in Aurora, Colorado. She has been practicing medicine for over 29 years. Dr. Knupp is rated as an Elite provider by MediFind in the treatment of Myoclonic Epilepsy. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses West Syndrome, Myoclonic Epilepsy, Spasmus Nutans, and Dravet Syndrome. Dr. Knupp is board certified in American Board Of Psychiatry And Neurology and American Board Of Psychiatry And Neurology. Dr. Knupp is currently accepting new patients.
Summary: ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham...
Summary: This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. ...